Alnylam submits cta application for aln-app, an investigational rnai therapeutic for the treatment of alzheimer's disease and cerebral amyloid angiopathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that the company has submitted a clinical trial authorization (cta) application to the medicines and healthcare products regulatory agency (mhra) in the united kingdom to initiate a phase 1 study of aln-app, an investigational rnai therapeutic targeting amyloid precursor protein (app) for the treatment of alzheimer's disease (ad) and cerebral amyloid angiopathy
ALNY Ratings Summary
ALNY Quant Ranking